Biostock has interviewed Chordate’s CEO, Anders Weilandt, about the study results from the company’s PM007 study, which have now been published in the journal Neurology, as well as the significance for the company’s valuation and ongoing exit process.
“It is absolutely crucial for the company’s overall value – and especially in the exit process – that we now have the evidence of Ozilia’s clinical efficacy published. This significantly boosts our marketing and sales efforts in our focus markets and reimbursement discussions. Most importantly, the exit process gains an invaluable addition: a highly compelling argument for why it makes sense to invest in acquiring this asset”, says Anders Weilandt to Biostock.